Secures $185M in Private Placement, In-Licenses CR-003 for $80M Upfront, and Out-Licenses CR-001

summarizeSummary

Crescent Biopharma announced a $185 million private placement, in-licensed a new ADC (CR-003) for $80 million upfront, and out-licensed CR-001 for $20 million upfront, significantly boosting its cash runway and pipeline while detailing clinical trial plans.

check_boxKey Events

• Secured $185 Million Private Placement

  On December 4, 2025, the company completed a private placement, issuing 13,664,251 ordinary shares and 131,434 pre-funded warrants for approximately $185 million in gross proceeds. This significantly enhances the company's capital position.

• In-Licensed CR-003 (SKB105) from Kelun

  On December 2, 2025, Crescent in-licensed exclusive rights to SKB105 (now CR-003), an integrin beta-6 directed ADC, outside Greater China from Kelun. The agreement includes an $80 million upfront payment and potential milestone payments up to $1.2475 billion.

• Out-Licensed CR-001 to Kelun for Greater China

  On December 2, 2025, Crescent granted Kelun an exclusive license to develop and commercialize CR-001 in Greater China. This deal includes a $20 million upfront payment to Crescent and potential development/regulatory milestones up to $30 million, plus tiered royalties.

• Terminated Previous CR-003 Agreement

  As a subsequent event on February 24, 2026, the company provided notice to terminate its ADC Paragon Option Agreement for the former CR-003, effective March 26, 2026, aligning its pipeline with the new Kelun CR-003 in-license.

auto_awesomeAnalysis

Crescent Biopharma, a clinical-stage biotechnology company, has filed its annual 10-K report, revealing a substantial $185 million private placement completed on December 4, 2025. This capital infusion significantly bolsters the company's liquidity, which stood at $213.2 million as of December 31, 2025, and is expected to fund operations for at least 12 months. The filing also details key strategic pipeline developments, including the in-licensing of SKB105 (now CR-003), an integrin beta-6 directed ADC, from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun) for an $80 million upfront payment and potential milestones up to $1.2475 billion. Concurrently, Crescent out-licensed its CR-001 bispecific antibody to Kelun for Greater China, receiving a $20 million upfront payment and potential milestones/royalties. This strategic move led to the termination of the previous ADC Paragon Option Agreement for the former CR-003, as disclosed in a subsequent event on February 24, 2026. The company is advancing its pipeline with a global Phase 1/2 trial for CR-001 initiated in February 2026, and anticipates initiating CR-002 and CR-003 monotherapy trials in 2026, with initial data expected in Q1 2027. While the company reported a net loss of $153.9 million for 2025, these financing and strategic transactions are critical for its long-term development and address immediate funding needs, positioning it for future clinical progress.